首页>投融资
Upstream Bio
上市
This company profile has not been updated since April 2013, when Upstream Biosciences was dissolved.Upstream Biosciences, founded in 2004, was a biotechnology company, focused on discovering, developing and licensing genetic markers for cancer susceptibility and drug response. In July 2009, Upstream formed an independent committee of the Board to assess the strategic direction of the company; however, in April 2013, the company was dissolved.The company previously maintained a website at http://www.upstreambio.com/ but this was no longer available by December 2011.The company was based in Vancouver, Canada.In August 2009, Upstream was actively seeking licensors or acquirers for its antiparasitic drug discovery portfolio and cancer diagnostic platform.In January 2008, Upstream Biosciences formed a collaboration with the Combinatorial Chemistry Center of the Chemistry Department of Lomonosov Moscow State University (MSU) for the chemical synthesis of novel co
基本信息
-
公司全称Upstream Biosciences Inc
-
类型免疫药物研发商
-
产业领域药品研发/制造、医药研发/制造、化学药
-
公司人数15~50人
-
地址Clark Wilson LLP 800-885 West Georgia Street Vancouver British Columbia V6C3H1; CA;
-
联系电话+1-800-539-0289
-
邮箱info@upstreambio.com
-
成立时间2004-01-01
投融资
-
2024-10-11上市2.55亿美元未透露
-
2023-06-08B轮2亿美元HBM HealthcareAccess IndustriesAltshuler Shaham GroupVenrock CapitalTCG X奥博资本德诚资本Omega FundsWellington ManagementEnavate SciencesBain CapitalSamsara BioCapital
-
2022-06-02A轮2亿美元Samsara BioCapitalOmega FundsHBM HealthcareTCG X奥博资本Access IndustriesMaruhoAltshuler Shaham Group德诚资本
相关投融资企业
上市
Septerna, founded in November 2021, is a biotechnology company focused on developing small molecule medicines targeting G protein-coupled receptors (GPCRs) for the potential treatment of multiple diseases, including endocrine, central nervous system and inflammation diseases.In July 2023, Septerna closed of a $150 million Series B financing.In January 2022, the company raised Series A financing of USD 100 million, led by Third Rock Ventures with support by Samsara BioCapital, BVF Partners, Invus Financial Advisors, Catalio Capital Management, Casdin Capital and Logos Capital
收并购
Modifi Biosciences is a developer of healthcare platform intended to exploit DNA defects in a wide range of cancer cells. The company's approach to fighting cancer is based on its ability to modify tumor DNA in a manner that is irreparable to cancer cells, without negatively impacting healthy cells, providing disrupting conventional oncology drug development.In October 2022, Modifi Biosciences has been selected by the National Cancer Institute for a Fast-Track Small Business Innovation Research Award of $2.4 million
A+轮
上海泽德曼医药科技有限公司成立于2021年6月30日，是一家全球性创新药物研发公司，专注于AhR靶点相关自身免疫炎症性疾病治疗药物的开发。公司的研发重点应用于中枢神经系统、五官、呼吸及皮肤等疾病的治疗领域
浙公网安备33011002015279
本网站未发布麻醉药品、精神药品、医疗用毒性药品、放射性药品、戒毒药品和医疗机构制剂的产品信息